What one share of C4 Therapeutics holds
We are a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation, or TPD, science to create a new generation of small-molecule medicines that transform patients’ lives.
C4 Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.31 |
|---|---|
| Profit | −$0.91 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$0.77 |
| Cash and investments | $0.64 |
| Book value | $2.01 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2019 | — | −$31.03 | $0.98 | $39.55 | — | −$78.48 |
| 2020 | — | −$5.83 | $0.06 | −$5.97 | — | — |
| 2021 | $0.99 | −$1.82 | $0.03 | −$1.92 | — | $8.00 |
| 2022 | $0.64 | −$2.62 | $0.11 | −$2.28 | — | $5.91 |
| 2023 | $0.42 | −$2.67 | $0.03 | −$2.19 | — | $4.07 |
| 2024 | $0.51 | −$1.52 | $0.00 | −$0.94 | — | $3.06 |
| 2025 | $0.43 | −$1.27 | $0.01 | −$1.20 | — | $2.65 |
Common questions about C4 Therapeutics
How much does one share of C4 Therapeutics earn?
Over the last 12 months, C4 Therapeutics lost $0.91 for each share on $0.31 of sales.
Does C4 Therapeutics pay a dividend?
C4 Therapeutics didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is C4 Therapeutics’s book value per share?
C4 Therapeutics’s book value is $2.01 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of C4 Therapeutics have?
Each share of C4 Therapeutics has $0.64 of cash and investments, as of June 30, 2026.
What is C4 Therapeutics’s free cash flow per share?
−$0.77 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has C4 Therapeutics bought back shares?
C4 Therapeutics’s share count rose about 5942% from 2019 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.